Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S.

Blood. 2011 Nov 10;118(19):5189-200. doi: 10.1182/blood-2011-02-339432. Epub 2011 Sep 12.

PMID:
21911831
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.

Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P, Grant S.

Blood. 2007 Sep 15;110(6):2092-101. Epub 2007 May 31.

PMID:
17540843
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, Grant S.

Blood. 2008 Sep 15;112(6):2439-49. doi: 10.1182/blood-2008-05-159392. Epub 2008 Jul 9.

PMID:
18614762
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.

Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S.

Blood. 2011 Feb 10;117(6):1947-57. doi: 10.1182/blood-2010-06-291146. Epub 2010 Dec 10.

PMID:
21148814
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Enhancing CHK1 inhibitor lethality in glioblastoma.

Tang Y, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2012 Apr;13(6):379-88. doi: 10.4161/cbt.19240. Epub 2012 Apr 1.

PMID:
22313687
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.

Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK.

Mol Cancer Ther. 2012 Aug;11(8):1781-8. doi: 10.1158/1535-7163.MCT-11-0949. Epub 2012 May 31.

PMID:
22653969
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.

Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2011 Aug 1;12(3):215-28. Epub 2011 Aug 1.

PMID:
21642769
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, LogiƩ A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16.

PMID:
22343622
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H.

J Clin Invest. 2012 Apr 2;122(4):1541-52. doi: 10.1172/JCI58765. Epub 2012 Mar 26. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.

PMID:
22446188
[PubMed - indexed for MEDLINE]
Free PMC Article
12.
13.

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ.

Sci Signal. 2011 Mar 29;4(166):ra17. doi: 10.1126/scisignal.2001752. Erratum in: Sci Signal. 2011;4(170). doi:10.1126/scisignal.4170er2. Corrected and republished in: Sci Signal. 2011;4(170):er2.

PMID:
21447798
[PubMed - indexed for MEDLINE]
Free Article
14.

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.

Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY, Choi J.

Invest New Drugs. 2013 Dec;31(6):1458-65. doi: 10.1007/s10637-013-0030-0. Epub 2013 Sep 26.

PMID:
24068620
[PubMed - indexed for MEDLINE]
15.

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.

Br J Haematol. 2010 May;149(4):537-49. doi: 10.1111/j.1365-2141.2010.08127.x. Epub 2010 Mar 12.

PMID:
20331454
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells.

Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY.

Eur J Pharmacol. 2011 Nov 30;670(2-3):356-64. doi: 10.1016/j.ejphar.2011.09.031. Epub 2011 Sep 19.

PMID:
21958871
[PubMed - indexed for MEDLINE]
17.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.

Blood. 2007 Sep 1;110(5):1656-63. Epub 2007 May 17.

PMID:
17510321
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

Sale MJ, Cook SJ.

Biochem J. 2013 Mar 1;450(2):285-94. doi: 10.1042/BJ20121212.

PMID:
23234544
[PubMed - indexed for MEDLINE]
Free Article
19.

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.

Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2013 May;14(5):458-65. doi: 10.4161/cbt.24424.

PMID:
23917378
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.

Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH.

Oncogene. 2005 May 5;24(20):3285-96.

PMID:
15735702
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk